BI Asset Management Fondsmaeglerselskab A S Lowers Position in CVS Health Corporation $CVS

BI Asset Management Fondsmaeglerselskab A S trimmed its stake in CVS Health Corporation (NYSE:CVS) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 373,299 shares of the pharmacy operator’s stock after selling 12,763 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in CVS Health were worth $28,059,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd raised its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC bought a new position in CVS Health in the 4th quarter valued at about $29,000. Dogwood Wealth Management LLC lifted its holdings in CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 179 shares during the last quarter. GoalVest Advisory LLC acquired a new stake in CVS Health in the 4th quarter valued at about $32,000. Finally, MidAtlantic Capital Management Inc. purchased a new stake in CVS Health during the fourth quarter valued at about $35,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CVS. Piper Sandler reissued an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research report on Monday. Mizuho lifted their price target on shares of CVS Health from $102.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. The Goldman Sachs Group lifted their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. TD Cowen boosted their price objective on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada boosted their target price on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $99.88.

Insider Activity

In related news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

CVS Health Trading Up 1.4%

Shares of CVS Health stock opened at $96.11 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43. The stock has a market cap of $122.62 billion, a PE ratio of 42.34, a PEG ratio of 0.93 and a beta of 0.62. The firm has a 50-day moving average of $84.13 and a 200-day moving average of $80.03.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the business earned $2.25 earnings per share. CVS Health’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.